Skip to main content
Bo Chen, MD, Pathology, Birmingham, AL, University of Alabama Hospital

BoChenMD

Pathology • Birmingham, AL

Anatomic Pathology, Clinical Pathology

Physician

Join to view full profile

Are you Dr. Chen?

Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.

  • Connect with colleagues in the same hospital or clinic
    You already have 4 invites waiting!
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

Claim this profile

Not you? Find your profile

Summary

  • Dr. Bo Chen, MD is a board certified pathologist in Birmingham, Alabama. He is currently licensed to practice medicine in Alabama, Florida, and Pennsylvania. He is affiliated with University of Alabama Hospital.

Education & Training

  • University of Alabama Medical Center
    University of Alabama Medical CenterResidency, Pathology-Anatomic and Clinical, 2016 - 2020
  • Qingdao University Medical College
    Qingdao University Medical CollegeClass of 1997

Certifications & Licensure

  • FL State Medical License
    FL State Medical License 2022 - 2026
  • PA State Medical License
    PA State Medical License 2021 - 2022
  • AL State Medical License
    AL State Medical License 2018 - 2021
  • American Board of Pathology Pathology - Anatomic/Pathology - Clinical

Publications & Presentations

PubMed

Press Mentions

  • Development of Prognosis Model for Colon Cancer Based on Autophagy-Related Genes
    Development of Prognosis Model for Colon Cancer Based on Autophagy-Related GenesOctober 30th, 2020
  • Cocaine-Induced Neural Adaptations in the Lateral Hypothalamic Melanin-Concentrating Hormone Neurons and the Role in Regulating Rapid Eye Movement Sleep After Withdrawal
    Cocaine-Induced Neural Adaptations in the Lateral Hypothalamic Melanin-Concentrating Hormone Neurons and the Role in Regulating Rapid Eye Movement Sleep After WithdrawalOctober 22nd, 2020
  • miR-200c Suppresses Stemness and Increases Cellular Sensitivity to Trastuzumab in HER2+ Breast Cancer
    miR-200c Suppresses Stemness and Increases Cellular Sensitivity to Trastuzumab in HER2+ Breast CancerOctober 10th, 2019

Hospital Affiliations

Dr. Bo Chen, Dr. Bo Chen, MD, Dr. B Chen